跳至主要内容
临床试验/EUCTR2021-005552-11-Outside-EU/EEA
EUCTR2021-005552-11-Outside-EU/EEA进行中(未招募)1 期

A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.

Genzyme Corporation0 个研究点开始时间: 2022年3月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • The patient's legal guardian must provide signed, informed consent prior to performing any study-related procedures;
  • The patient must have a confirmed diagnosis of Pompe disease as determined by deficient endogenous acid alpha-glucosidase (GAA) activity or GAA mutation analysis; and
  • The patient must be <1 year of age at time of study enrollment (and receive alglucosidase alfa treatment before 1 year of age), or the patient must be between 1 year and 24 months of age and must have initiated alglucosidase alfa treatment prior to turning 1 year of age.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 15
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The patient is participating in another clinical study using alglucosidase alfa or any investigational therapy.

研究者

相似试验